AZN AstraZeneca PLC
USHealthcareAs of 2026-07-10 16:00
Why AZN matters now
AstraZeneca PLC (AZN) is a US stock in Healthcare. The latest InvestLog snapshot shows $171.61 with -3.85% on the session and $266.15B in market capitalization; recent performance reads 1-month -5.26% and YTD -0.32%.
The latest financial table shown here is Q1 2026, with revenue of $15.29B, net income of $3.08B, and EPS of $1.97. Investors can compare that operating picture with valuation signals such as P/E 30.93 and FCF yield 2.9%.
The latest indexable market news headline is "Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $185.00; recent insider activity includes Sharma Mani filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
30.93
PEG
0.68
P/B
5.73
P/S
4.47
EV/EBITDA
14.51
DCF Value
$563.39
FCF Yield
2.9%
Div Yield
1.8%
Margins & Returns
Gross Margin
79.7%
Operating Margin
23.5%
Net Margin
17.2%
ROE
22.4%
ROA
9.2%
ROIC
12.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.29B | $3.08B | $1.97 |
| Q4 2025 | $15.50B | $2.33B | $1.48 |
| FY 2025 | $58.74B | $10.26B | $6.54 |
| Q3 2025 | $15.19B | $2.53B | $1.62 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$186.67
Target (Median)
$185.00
Target Range
$158.00 - $216.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
GB
Exchange
—
Beta
0.21
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.